Korean J Thorac Cardiovasc Surg.
2006 Sep;39(9):668-673.
Cell Death Induction Mechanism of Non-small Cell Lung Cancer Cell Line, NCI-H1703 by Docetaxel
- Affiliations
-
- 1Department of Thoracic and Cardiovascular Surgery, College of Medicine, Pusan National University, Korea. domini@pnu.edu
Abstract
-
BACKGROUND: Docetaxel has been effectively used as an anti-cancer chemotherapuetic agent for various tumor treatments including lung cancer. However, the cell death induction mechanism(s) involved with docetaxel treatment in lung cancer cells has not been known yet.
MATERIAL AND METHOD: In the present study, the cellular and biochemical changes of NCI-H1703 cells (non-small cell lung cancer cell line, p53-mutant) after docetaxel treatment have been monitored by flow cytometry, fluorescence microscopy and western blot.
RESULT: Docetaxel treatment significantly resulted in decrease of S phase as well as increase of G2 phase, and consequently evoked an increase of cell death in NCI-H1703 cells. After docetaxel exposure the activations of caspase-3 and caspase-9 were detected.
CONCLUSION
Take together, it is suggested that the docetaxel induces NCI-H1703 cell death by caspase-9 and caspase-3 dependent mitochondrial apoptotic pathway.
- Full Text Links
-
- Actions
-
Cited
- CITED
-
- Close
- Share
-
- Similar articles
-
- Treatment of Advanced and Metastatic Squamous Non-small Cell Lung Cancer
- Growth Inhibition and Apoptosis Induction of Sulindac on Human Lung Cancer Cells
- Docetaxel as Second-line Monotherapy for Advanced Non-small Cell Lung Cancer
- Comparison of Gefitinib versus Docetaxel in Patients with Pre-Treated Non-Small Cell Lung Cancer (NSCLC)
- The Anti-tumor Effect of Macrolides on the Extracellular Matrix Invasion and Cell Adhesion in Human Non-small Cell Lung Cancer Cells
